Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.58 |
| ▸ | FLT3 | P36888 | 1/20 | 0.55 |
| ▸ | TNF | P01375 | 1/20 | 0.55 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.55 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.55 |
| ▸ | IDO1 | P14902 | 5/20 | 0.54 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.50 |
| ▸ | PPARG | P37231 | 2/20 | 0.49 |
| ▸ | F2 | P00734 | 1/20 | 0.49 |
| ▸ | F10 | P00742 | 1/20 | 0.49 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.49 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.49 |
| ▸ | CNR1 | P21554 | 1/20 | 0.48 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1607589 | 0.90 | HDAC1 (0.73) | HDAC1HDAC6FLT3TNFCYP11B1 | |
| SCHEMBL1608848 | 0.87 | CYP11B1 (0.60) | HDAC1HDAC6FLT3TNFCYP11B1 | |
| SCHEMBL30202437 | 0.84 | BRD4 (0.59) | HDAC1HDAC6FLT3TNFCYP11B1 | |
| SCHEMBL17807884 | 0.84 | BRD4 (0.59) | HDAC1HDAC6FLT3TNFCYP11B1 | |
| SCHEMBL17813526 | 0.82 | HDAC1 (0.50) | HDAC1HDAC6FLT3TNFCYP11B1 | |
| SCHEMBL18898696 | 0.80 | HDAC1 (0.48) | HDAC1HDAC6FLT3TNFCYP11B1 | |
| SCHEMBL1607561 | 0.80 | HDAC1 (0.62) | HDAC1HDAC6FLT3IDO1CNR1 | |
| SCHEMBL1608602 | 0.79 | SMN1; SMN2 (0.60) | HDAC1HDAC6FLT3TNFCYP11B1 | |
| SCHEMBL30202327 | 0.79 | CYP11B1 (0.51) | HDAC1HDAC6FLT3TNFCYP11B1 | |
| SCHEMBL28987154 | 0.79 | CYP11B1 (0.51) | HDAC1HDAC6FLT3TNFCYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210177855-A1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS LTD. (CA) | 2021-06-17 | — | — | US | disclosed |
| US-10772892-B2 | Bicyclic bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2020-09-15 | — | — | US | disclosed |
| US-10363257-B2 | Bicyclic bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2019-07-30 | — | — | US | disclosed |
| US-10010556-B2 | Bicyclic bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2018-07-03 | — | — | US | disclosed |
| US-10010556-B2 | Bicyclic bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2018-07-03 | — | — | US | disclosed |
| US-20180161337-A1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | RVX THERAPEUTICS INC. (CA) | 2018-06-14 | — | — | US | disclosed |
| US-20180161337-A1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | RVX THERAPEUTICS INC. (CA) | 2018-06-14 | — | — | US | disclosed |
| US-20170216301-A1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS LTD. | 2017-08-03 | — | — | US | disclosed |
| US-20170216301-A1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS LTD. | 2017-08-03 | — | — | US | disclosed |
| US-9663520-B2 | Bicyclic bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2017-05-30 | — | — | US | disclosed |
| US-9663520-B2 | Bicyclic bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2017-05-30 | — | — | US | disclosed |
| US-20160159801-A1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS CORP. | 2016-06-09 | — | — | US | disclosed |
| US-20160159801-A1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS CORP. | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10363257-B2 | Bicyclic bromodomain inhibitors | BRD4, BRD3, BRD2 | HDAC1 34/4885HDAC6 125/4885FLT3 903/4885 |
| US-10010556-B2 | Bicyclic bromodomain inhibitors | BRD4, BRD3, BRD2 | HDAC1 34/4885HDAC6 125/4885FLT3 903/4885 |
| US-10772892-B2 | Bicyclic bromodomain inhibitors | BRD4, BRD3, BRD2 | HDAC1 34/4885HDAC6 125/4885FLT3 903/4885 |
| US-20180161337-A1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD2 | HDAC1 30/4885HDAC6 140/4885FLT3 1121/4885 |
| US-20170216301-A1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD2 | HDAC1 30/4885HDAC6 140/4885FLT3 1121/4885 |
| US-20210177855-A1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD2 | HDAC1 30/4885HDAC6 140/4885FLT3 1121/4885 |
| US-20160159801-A1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD2 | HDAC1 30/4885HDAC6 140/4885FLT3 1121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.